The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid ...

Robert F. Kennedy, Jr.’s recent disclosures have revealed several potential conflicts of interest, including investments in ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p ...